Hydroxamate inhibitors of the matrix metallo-proteinases (MMPs) containing novel P 1′ heteroatom based modifications

• Published in: Bioorganic & medicinal chemistry letters Vol. 5; no. 4; pp. 343 - 348
• Main Authors: Tomczuk, Bruce E., Gowravaram, Madhusudhan R., Johnson, Jeffrey S., Delecki, Daniel, Cook, Ewell R., Ghose, Arup K., Mathiowetz, Alan M., Spurlino, John C., Rubin, Byron, Smith, Douglas L., Pulvino, Tricia, Wahl, Robert C.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 16-02-1995
• ISSN: 0960-894X; 1464-3405
• DOI: 10.1016/0960-894X(95)00032-O

Structure-based drug design (SBDD) and traditional SAR have guided the development of potent and selective hydroxamate inhibitors which contain heteroatom-based modifications of the P
1′ group. These inhibitors may help delineate the
in vivo roles of specific MMPs in normal and disease states.
Design and synthesis of novel heteroatom-based P
1' hydroxamate inhibitors of the matrix metalloprotcinases.